# Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

> **NCT01993641** · PHASE2 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 45 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- MDS

## Interventions

- **DRUG:** pracinostat
- **DRUG:** Azacitidine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT01993641
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-05
- **Final completion:** 2016-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01993641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01993641, "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT01993641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*